内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Diabetologia：代谢综合征严重程度评分与未来糖尿病之间相关性

2017-06-21 MedSci MedSci原创

糖尿病代谢综合征
关注

近日，国际杂志 《Diabetologia》上在线发表一项关于代谢综合征严重程度评分与未来糖尿病之间相关性的研究。旨在该研究旨在评估代谢综合征的严重程度与2型糖尿病风险之间的关系，除由代谢综合征的各个组分所导致的风险。

近日，国际杂志 《Diabetologia》上在线发表一项关于代谢综合征严重程度评分与未来糖尿病之间相关性的研究。旨在该研究旨在评估代谢综合征的严重程度与2型糖尿病风险之间的关系。 研究人员对随访时间中位数超过7.8年的两个观察队列（社区动脉粥样硬化风险研究（n = 10,957）和杰克逊心脏研究（n = 2137））中的参与者进行研究，并评估了成人治疗组III（ATP-III）的代谢综合征评分（ATP-III MetS）的HR值，以及与糖尿病相关的性别和种族特异性连续代谢综合征严重程度z评分。 ATP-III MetS糖尿病的HR为4.36（95％CI 3.83,4.97），其在包括个体代谢综合征成分的模型中有所减弱。相比之下，第四类代谢综合征严重程度（与第一类相比）的参与者未来糖尿病的HR为17.4（95％CI 12.6,24.1）; 在还包括个体代谢综合征成分的模型中，这仍然是很重要的，该模型中HR为3.69（95％CI 2.42,5.64）。在这些模型中有一个种族×代谢综合征相互作用，黑人参与者（5.30）的HR比白人（2.24）更高。 当代谢综合征严重程度评分的变化包括在危险

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1637823, encodeId=aeb8163e823e3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue May 08 13:09:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837268, encodeId=f57f183e268b0, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Feb 25 22:09:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760029, encodeId=90d61e600296b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Oct 13 20:09:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430860, encodeId=89ca1430860c7, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jun 23 10:09:00 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2018-05-08 ms9608593228839890

    #DIA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1637823, encodeId=aeb8163e823e3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue May 08 13:09:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837268, encodeId=f57f183e268b0, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Feb 25 22:09:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760029, encodeId=90d61e600296b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Oct 13 20:09:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430860, encodeId=89ca1430860c7, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jun 23 10:09:00 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2018-02-25 shenxlcyp

    #相关性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1637823, encodeId=aeb8163e823e3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue May 08 13:09:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837268, encodeId=f57f183e268b0, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Feb 25 22:09:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760029, encodeId=90d61e600296b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Oct 13 20:09:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430860, encodeId=89ca1430860c7, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jun 23 10:09:00 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2017-10-13 ms5439512287675881

    #BET#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1637823, encodeId=aeb8163e823e3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue May 08 13:09:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837268, encodeId=f57f183e268b0, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Feb 25 22:09:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760029, encodeId=90d61e600296b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Oct 13 20:09:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430860, encodeId=89ca1430860c7, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jun 23 10:09:00 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2017-06-23 zhouqu_8

    #综合征#

    0

相关资讯

Diabetes：Kv2.1集群有助于胰岛素胞外分泌同时可以缓解人类β类细胞功能障碍

胞外分泌胰岛素是由控制兴奋性和Ca2 +涌入的离子通道调控的。这些通道在调控膜质微区结构方面也有重要作用。本次研究中我们探究了INS 832/13细胞和β型细胞中K+ (Kv) 通道Kv2.1 (KCNB1)促进去极化诱发胞外分泌的机制，这些细胞来源于没患和患有2型糖尿病(T2D)的捐赠者。

JAMA Intern Med：血糖自我监测无益于非胰岛素治疗的II型糖尿病患者的血糖控制

研究发现对于非胰岛素治疗的II型糖尿病患者，血糖自我监测对1年的糖化血红蛋白水平和健康相关的生活质量无显著影响。血糖自我监测与自动信息反馈对血糖控制未体现出优势

Cell Metab:糖尿病治疗新思路：让胰岛β细胞“High”起来

最近，加州大学圣地亚哥分校（UCSD）的研究人员采用单细胞RNA测序，首次揭示了调控胰岛β细胞生长的信号通路，有望以此诱导其再生，从而为糖尿病的治疗带来了新的线索。这一成果发表在《细胞》子刊《Cell Metabolism》上。

Circulation：糖尿病心血管疾病患者的危险因素和预后的关系

改变一些危险因素可以显着改善伴有糖尿病的心血管患者的预后。但是，将这些危险因素改变到什么程度才能最大化改善预后仍没有大型的临床试验数据支持。

Hypertension：糖尿病患者应用β受体阻滞剂增加心血管风险

Hypertention发表ACCORD研究最新分析数据显示，不管有无基础心血管疾病，糖尿病患者应用β受体阻滞剂均增加不良心血管事件风险，而且应用β受体阻滞剂的患者的严重低血糖发生率明显高于未应用β受体阻滞剂的患者。

儿童青少年2型糖尿病诊治中国专家共识

由于儿童青少年肥胖者日益增多，儿童青少年2型糖尿病发病率随之上升。但是，儿童青少年2型糖尿病诊治和管理面临众多挑战，如临床表现重叠、分型困难等。为了进一步规范儿童青少年2型糖尿病的诊断、评估和治疗，中华医学会儿科学分会内分泌遗传代谢学组组织专家制订了《儿童青少年2型糖尿病诊治中国专家共识》，该共识对推进儿童青少年2型糖尿病的规范化管理和临床诊疗具有一定价值。